Significantly Longer Survival In Refractory Breast Cancer With The Addition Of Eganelisib To Standard Treatment!

The addition of the new drug Eganelisib to Atezolizumab in combination with albumin paclitaxel significantly prolonged progression-free survival in patients with metastatic triple-negative breast cancer, according to updated data from a phase 2 trial.

Eganelisib (IPI-549), a class I innovation, is an oral PI3K-γ inhibitor that primarily targets M2 macrophages in the breast cancer microenvironment. M2 macrophages suppress the effects of immunotherapy, while Eganelisib converts M2 into more cancer-friendly M1 cells, thereby downregulating immunosuppression, increasing immune activity and promoting killer T-cell activation and proliferation.

The trial is a MARIO-3 study with a single patient group, all patients enrolled were treated with oral Eganelisib in combination with Atezolizumab+albumin paclitaxel.

Follow-up of the enrolled patients for a mean of 10 months revealed that the proportion of patients with no further disease exacerbation for up to 1 year was 36%. This compares with 23.7% of patients treated with Atezolizumab + albumin paclitaxel alone for 1 year in the previous IMpassion130 study. This means that the addition of Eganelisib resulted in a 52% improvement in the disease profile of patients.

The proportion of PD-L1 positive patients with sustained 1 year disease free exacerbation was 37.5%, compared to 29.1% for Atezolizumab + albumin paclitaxel treatment in the IMpassion130 study. This means that the addition of Eganelisib resulted in a 29% improvement in the patient's disease profile.

Among PD-L1-negative patients, the proportion of patients with sustained 1-year disease without exacerbation was 34.7%.

"It is pleasing to see that Eganelisib + standard of care treatment, significantly prolonged progression-free survival, benefiting patients regardless of their PD-L1 status."

This updated data also shows that the addition of Eganelisib resulted in substantial tumour shrinkage in 66.7% of PD-L1-positive patients. And in the IMpassion130 trial, treatment with Atezolizumab + albumin paclitaxel alone resulted in substantial tumour shrinkage in 58.9% of patients.

In PD-L1-negative patients, the addition of Eganelisib resulted in substantial tumour shrinkage in 54.3% of patients.
Common side effects of treatment included fatigue, adverse skin reactions, nausea, hepatotoxicity, diarrhoea, alopecia, neutropenia, vomiting, fever, peripheral neuropathy, stomatitis, and decreased appetite.

In addition to triple-negative breast cancer, the addition of Eganelisib has led to better survival outcomes in both uroepithelial carcinoma and immune checkpoint inhibitor-refractory head and neck squamous cell carcinoma, all of which suggest that Eganelisib can prolong long-term survival for patients.